Platinum resistant recurrent ovarian cancer

Author: uoxv

August undefined, 2024

Webbför 2 dagar sedan · As part of the phase 3 GLORIOSA study (NCT05445778), a clinical trial is evaluating the safety and efficacy of the antibody drug conjugate (ADC) mirvetuximab soravtansine (Elahere) as maintenance therapy for patients with folate receptor-alpha (FRα)-positive recurrent platinum-sensitive ovarian cancer. 1 In the multicenter, open … WebbResistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer, contributing to the high mortality-to-incidence ratio. Management of the …

Treatment of platinum-resistant ovarian cancer - PubMed

WebbPurpose: To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum-resistant ovarian cancer in a real-world setting. Patients and methods: We … WebbOf the 38 women enrolled, 18 had platinum-resistant with an ORR of 16.7% (95% CI 3.6–41.4%) compared to an ORR of 40% in platinum-sensitive cohort. Median PFSPFS by … lyrics peter bjorn and john

Innovative therapies to tackle platinum-resistant ovarian …

Webb10 apr. 2024 · Treatment with botensilimab plus balstilimab produced responses in patients with refractory or resistant ovarian cancer, according to results from a phase 1 study. Adding the T-cell primer to the PD-1 inhibitor led to objective responses in a third of patients with recurrent platinum-refractory/resistant ovarian cancer. WebbThe mainstay of treatment for platinum-resistant ovarian cancer is single agent chemotherapy. Other treatment modalities have tested in this setting with discouraging … WebbAfter recurrence, response rates to second-line chemotherapy for platinum-sensitive patients are 30% or higher; however, patients with platinum-resistant disease have significantly lower response rates of 10%-25% to chemotherapeutic agents, such as liposomal doxorubicin, topotecan, taxanes, etoposide, and gemcitabine [ 2 ]. kirkland nws weather

Adavosertib plus gemcitabine for platinum-resistant or …

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: …

WebbOne solution to improve treatment for platinum-resistant ovarian cancer would be the development of precision medicine. 14–16 Since the odds associated with this type of … Webb23 jan. 2024 · Background: The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We … lyrics people who diedWebb29 juni 2024 · About Platinum-Resistant Ovarian Cancer Ovarian cancer is the fifth most common cause of cancer death in women. 1 Patients whose disease returns less than six months after receiving... lyrics perfume lovejoy

"WebbDiscussion. The AVF 2949g trial was a clinical study on platinum-resistant recurrent ovarian cancer. Because GI perforation was observed in five (23.8%) of the 21 patients … " - Platinum resistant recurrent ovarian cancer

Platinum resistant recurrent ovarian cancer

Real‐world outcomes of niraparib treatment in patients with ovarian …

Webbför 8 timmar sedan · A phase 1b study (NCT05226507) examining the safety, tolerability, and preliminary efficacy of NXP800 in patients with platinum-resistant, ARID1a-mutated … WebbPujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al.. (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian …

Did you know?

Webb11 apr. 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer.MethodsPubmed, … Webb26 apr. 2024 · The aim of treatment in recurrent or refractory epithelial ovarian cancer is palliation. In a patient with platinum-resistant status, several chemotherapy regimens have been reported with similar response rates. Among these agents, the oral etoposide holds an advantage of the route of administration and management in the out-patient setting.

Webb2 feb. 2024 · There are a number of approaches to develop effective and tolerable medicines in platinum-resistant recurrent ovarian cancer—at least 4 come to mind. Tumor treating fields are active in chemotherapy-resistant tumors such as glioblastoma multiforme in thoracic mesothelioma. WebbIntroduction: Platinum-resistant ovarian cancer (PROC) is broadly defined as disease recurrence within 6 months of completing platinum-based chemotherapy, either in the …

Webb9 mars 2024 · For patients with platinum-sensitive recurrent ovarian cancer, we usually choose carboplatin (carbo) in combination with paclitaxel (PAC) as the first-line standard chemotherapy regimen, but this regimen exhibits more non-hematologic toxicity, which results in early discontinuation of treatment. Webb9 sep. 2024 · The congress will take place from September 16 – 21, 2024. “We are extremely excited by the potential of relacorilant to treat women with recurrent platinum-resistant ovarian cancer,”...

WebbAbstract. "Platinum resistant" ovarian cancer was historically defined as disease recurrence within 6months of completion of first-line platinum-based chemotherapy, although this is …

WebbBackground: The purpose of this study was to observe the role of secondary cytoreductive surgery in platinum-resistant recurrent ovarian cancer (OC) patients. Methods: We … kirkland obituary sneads floridaWebb23 jan. 2024 · However, platinum-resistant recurrent ovarian cancer remains a clinical challenge with few effective therapeutic options. The DNA and RNA helicase Schlafen family member 11 (SLFN11) has been studied for its potential role in translation of DNA damage response proteins. lyrics persephoneWebbPlatinum-resistant recurrent ovarian cancer has a poor prognosis, but combined therapy with bevacizumab and anticancer agents may be useful. We report a patient with long … lyrics phantom nnocWebb4 mars 2024 · Platinum resistant means your cancer comes back within 6 months of finishing your last carboplatin treatment. Your doctor might describe your cancer as: … kirkland ocusight reviewsWebb11 apr. 2024 · Niraparib was authorized as a maintenance treatment for platinum-sensitive recurrent ovarian cancer in December 2024 and as first-line maintenance therapy in October 2024 in China . At the beginning of the study period, due to economic reasons, niraparib was often reserved as a last resort when patients were resistant or intolerable … kirkland ny town hallWebb27 juni 2024 · Based on criteria from the Fourth Ovarian Cancer Consensus Conference, patients are considered platinum refractory if the interval between the last dose of a … kirkland ocean spray cranberry juiceWebbOf the 38 women enrolled, 18 had platinum-resistant with an ORR of 16.7% (95% CI 3.6–41.4%) compared to an ORR of 40% in platinum-sensitive cohort. Median PFSPFS by RECIST was 7.7 months in PROC vs 12.1 months in platinum-sensitive patients. Nine participants (23.7%) experienced a grade 3 or higher TRAEs. 37. lyrics phantom 309